AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABCL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.16B
- EPS (TTM)
- -$0.48
- Dividend yield
- None
- 52-week range
- 2.75 – 15.02
- Day range
- 9.58 – 10.26
- Volume / Avg
- 4.24M / 4.34M
- Beta
- —
- Shares outstanding
- 326.62M
52-week range
ABCL stock today
Shares of AbCellera Biologics (ABCL) finished lower on Nov 20 at $9.69, a drop of 7.45% or $0.78 per share, versus the S&P 500's 3.70% decline. At this level, ABCL sits in the middle of its 52-week range of $2.75 to $15.02: 35.5% below the high, set on Sep 30, 2026 and 253.0% above the low. ABCL is up 183.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 176.1%.
AbCellera Biologics has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AbCellera Biologics
Company profileAbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Headquarters
- Vancouver, BC
- Employees
- 562
- IPO year
- 2020
- Website
- abcellera.com
Financial highlights
Full financialsIn fiscal 2025, AbCellera Biologics generated $75.1 million in revenue, up 160.6% from fiscal 2024. AbCellera Biologics reported a net loss of $146.4 million, compared with a loss of $162.9 million a year earlier. Operating margin was -289.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M |
| Growth | +160.56% | -24.17% | -92.17% | +29.38% | +60.92% |
| Net income | $-146.41M | $-162.86M | $-146.40M | $158.52M | $153.46M |
| EPS (diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$18.67+92.67%
- Strong buy 2
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.13 vs $-0.18
- Surprise
- +27.78%
ABCL news
All ABCL newsAbCellera Biologics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs ABCL |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs ABCL |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs ABCL |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs ABCL |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs ABCL |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs ABCL |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs ABCL |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs ABCL |
Indexes, lists and sector
AbCellera Biologics stock FAQ
What is AbCellera Biologics's stock price today?
ABCL last traded at $9.69 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.
Who is AbCellera Biologics's CEO?
Dr. Carl L.G. Hansen Ph.D. is the chief executive officer of AbCellera Biologics Inc., which has about 562 employees.
What is the ABCL 52-week high?
The 52-week high for ABCL is $15.02 and the 52-week low is $2.75. The stock is currently 35.5% below its high.